The world’s first fused erbium laser, bringing a new approach to laser facial rejuvenation
BTL, a global leader in advanced energy-based medical and aesthetic technologies, today announced a major milestone in its corporate history: the official establishment of its dedicated laser division and the upcoming launch of its flagship laser system, EXOLASE ONE®.
EXOLASE ONE® is a major leap in the aesthetic industry as the first-ever application of fused erbium laser technology in medical practice. The system fuses multiple erbium laser wavelengths into a single beam of light, treating the exact same spot simultaneously. This creates a completely new form of laser-tissue interaction that overcomes the traditional limitations of existing facial rejuvenation lasers regarding clinical efficacy, speed of treatment, and patient comfort.
“The technology covers what normally requires multiple ablative and non-ablative systems, transforming it into a remarkably simple procedure that treats the entire face in under 10 minutes while delivering superior results for our patients,” said Dr. Reha Yavuzer, one of the first clinical investigators for the platform.
EXOLASE ONE® is the latest high-tech breakthrough originating from BTL’s extensive R&D infrastructure, which has powered many of the company’s industry-defining innovations.
“This is a historic moment for BTL. From the beginning, we knew that only a genuinely disruptive technology would allow us to build a true laser powerhouse,” said Tomas Schwarz, CEO of BTL Group of Companies. “Based on feedback from pioneering clinical centers worldwide, EXOLASE ONE® represents exactly this kind of breakthrough.”
Following an early-access program for selected key opinion leaders, EXOLASE ONE® will move to a broader global launch in 2027, initially focused on aesthetic medicine and dermatology. The new laser division becomes BTL’s sixth core division, complementing its existing operations in aesthetics, mental wellness, rehabilitation, cardiology, and robotics.
